Government Funding to Back Growth of the Global Influenza Drugs and Vaccines Market

Published Date : Jun 12, 2017

Albany, New York, June 12, 2017: has announced the addition of a report, titled “Global Influenza Drugs And Vaccines Market - By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) - Analysis By Region, By Country: Opportunities And Forecast (2016-2021) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan),” to its database. The findings of the report indicate that the global influenza drugs and vaccines market will expand at a CAGR of 10.24% between 2017 and 2022.

The global market for influenza drugs and vaccines is gaining significant momentum due to the rising awareness among people worldwide regarding pandemic influenza virus along with the increasing healthcare expenditure. Governments worldwide are pouring funds into the development of drugs and vaccinations against influenza virus. Besides this, various non-government organizations and market players are also involved in extensive research and development activities to introduce safe and efficacious drugs and vaccines. Moreover, rapid technological advancements in the field of DNA technology are providing a fillip to the global influenza drugs and vaccines market.

On the flip side, the stringent regulatory framework in several countries worldwide delays the approval of drugs and vaccines. This is acting as a stumbling block for the growth of the global influenza drugs and vaccines market. Furthermore, despite the constant efforts of governments, the accessibility to remote areas is low, especially in developing countries, which in turn is inhibiting the growth of the market. However, the presence of a large population base with no immunization against influenza viruses in developing countries is rendering their markets highly opportunistic.

For Sample Copy, click here:

On the basis of drugs, the global influenza drugs and vaccines market is divided into oseltamivir phosphate, zanamivir, and peramivir. Based on vaccine, the market is bifurcated into quadrivalent and trivalent. In terms of country, the market is categorized into the U.K., Canada, the U.S., Japan, India, France, Germany, and China.

By region, the market is classified into Europe, Asia Pacific, North America, and Rest of the World. North America will account for a large share in the global arena owing to the high awareness regarding influenza virus among the populace and the presence of an advanced research and development infrastructure. Asia Pacific, on the other hand, will exhibit a significant CAGR during the forecast period, due to the high unmet needs coupled with the increasing government investments in the development of influenza drugs and vaccines.

The majority of key players in the global influenza drugs and vaccines market are paying high attention to industrialized countries. However, they are also targeting untapped emerging markets to maximize their profit and consolidate their position worldwide. To withstand the fierce competition in these markets, companies are participating in health programs and technological transfers and are outsourcing joint development activities. Several market participants are also banking on mergers and acquisitions and development of novel drugs and vaccines to expand their business.

The prominent companies operating in the global influenza drugs and vaccines market that are profiled in the report are Sanofi Pasteur Inc., AstraZeneca, Serum Institute Of India Pvt. Ltd., Emergent Biosolutions, Alvogen, BioCryst Pharmaceuticals Inc., Protein Sciences Corporation, CSL Limited, and GlaxoSmithKline.

To order report Call Toll Free: 866-997-4948 or send an email on